Physician profile
Mark Edgcomb
NPI 1477967404
$4,034.89
in general payments reported to CMS, 2019-2025
14 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $111 · 2021: $1,316 · 2022: $389 · 2023: $1,197 · 2024: $763 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926 · Long Term Medical Supply Or Device Loan: $726 · Travel and Lodging: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.95 |
| Long Term Medical Supply Or Device Loan | $726.30 |
| Travel and Lodging | $566.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,946.11 | 2021-2023 | Da Vinci Surgical System |
| Integra Lifesciences Corporation | $877.89 | 2022-2025 | Acell, Integra, Surgimend |
| W. L. Gore & Associates, INC. | $208.00 | 2021 | |
| Medtronic, INC. | $201.66 | 2022-2023 | Ligasure |
| Kerecis Limited | $160.63 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Tela Bio, INC. | $153.14 | 2021 | |
| Ethicon US, LLC | $124.92 | 2022 | |
| Abbvie INC. | $123.73 | 2023 | Alloderm |
| Acell, INC. | $111.26 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.79 | 2022 | |
| Merck Sharp & Dohme LLC | $36.57 | 2022 | |
| Braintree Laboratories, INC. | $25.27 | 2022 | |
| Mauna Kea Technologies, INC. | $17.18 | 2024 | |
| Kls-Martin L.P. | $6.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Edgcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.